Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IND Flu Vaccines Not Recommended For Routine Use, CDC Says

Executive Summary

Flu vaccines supplied under investigational new drug applications are not well-suited for routine use, a Centers for Disease Control & Prevention official told the National Vaccine Advisory Committee in Washington, D.C. June 7

You may also be interested in...



MedImmune Emerges As Potential Takeover Target With Vaccines, Synagis

MedImmune's growing vaccine franchise and recently revised co-marketing arrangement for Synagis (palivizumab) may position the firm well for a takeover

MedImmune Emerges As Potential Takeover Target With Vaccines, Synagis

MedImmune's growing vaccine franchise and recently revised co-marketing arrangement for Synagis (palivizumab) may position the firm well for a takeover

GSK Vaccine Portfolio Gets A Shot In The Arm From ID Biomedical Buy

GlaxoSmithKline's proposed acquisition of ID Biomedical, announced Sept. 7, will bolster the drug maker's growing vaccine portfolio with the addition of Fluviral and several pipeline products

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel